1Cell.Ai
1Cell.Ai is a precision oncology company that applies AI-driven single-cell multi-omics (genomic, transcriptomic, proteomic) to cancer diagnostics, serving clinicians, biopharma partners, and cancer patients through CLIA-certified US and NABL-accredited India laboratories.
- Company typePrivate
- Founded2019
- HeadquartersMumbai, India
- Headcount101–250
- GTM typeB2B
- OfferingServices
What 1Cell.Ai does
1Cell.Ai is a precision oncology company that applies AI to single-cell multi-omic analysis for cancer diagnostics. Originally founded as OneCell Diagnostics in 2019 and rebranded in April 2025, the company operates a CLIA/CAP certified laboratory in Foster City, California and an NABL accredited laboratory in Pune, India, with a regional headquarters in Mumbai. Its core technology stack combines a proprietary live circulating tumor cell (CTC) capture platform (Cell Biopsy®, OncoIncytes®) achieving over 82% single-cell capture efficiency, an AI-driven automated single-cell isolation system (1Cell SOLO®), and an AI-powered informatics platform (1Cell iCore™ with iDiscover and iCare modules) that integrates genomic, transcriptomic, proteomic, imaging, and clinical data with real-world evidence. AI capabilities span deep-learning digital pathology (OncoPredikt, TRINITYAI), ctDNA methylation-driven MRD detection (MIRAGE), predictive therapy response modeling, and variant interpretation ML.
The company's product portfolio is organized into a global platform (OncoIncytes, 1Cell SOLO, 1Cell iCore) and an India-focused diagnostic suite (OncoIndx comprehensive 1,000+ gene NGS profiling, OncoIndx Prime+ matched tissue-liquid-normal NGS, OncoRisk hereditary 74-gene panel, OncoHRD for PARP inhibitor guidance, OncoMonitor longitudinal CTC/ctDNA monitoring, OncoTarget disease-specific panels, OncoIndx 360° Endometrium, and DrG/OSakhi clinician and patient companion platforms). All tests are supported by AI-powered interpretation through the iCare™ platform and validated under CAP/CLIA/NABL/ISO quality systems.
Revenue is generated through three streams: one-time diagnostic testing services sold quote-based to hospitals and oncologists, clinical research and biomarker discovery services for biopharma partners, and recurring biopharma partnerships for trial support and companion diagnostic development. GTM is enterprise field sales augmented by active presence at major oncology conferences (AACR, SABCS, ESMO, ISLB, World ADC). Strategic alliances include BioSkryb Genomics (single cell multi-omics co-development, April 2025), AccuGenomics (Accukit integration for Asia scale-up, October 2025), and Georgia Cancer Centre (CLIA-grade validation, May 2025). Customers served include 100+ hospitals, 1,000+ clinicians, and 50,000+ patients cumulatively, with primary segments being clinicians/oncologists and pharma/biopharma partners.
1Cell.Ai firmographics
Firmographics- Name
- 1Cell.Ai
- Legal name
- 1Cell.Ai Inc.
- Website
- https://1cell.ai
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- 1Cell.Ai is a precision oncology company that applies AI-driven single-cell multi-omics (genomic, transcriptomic, proteomic) to cancer diagnostics, serving clinicians, biopharma partners, and cancer patients through CLIA-certified US and NABL-accredited India laboratories.
- Ownership category
- akta.pro rank
1Cell.Ai industry classification
Industry- Product category
- Precision Oncology Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where 1Cell.Ai is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices5 records
Markets served
1Cell.Ai business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Testing Services: Revenue generated from comprehensive genomic profiling tests including OncoIndx (1000+ gene panel), OncoIndx Prime+, OncoRisk (hereditary cancer testing), OncoHRD, OncoMonitor (longitudinal monitoring), and OncoTarget. Tests offered for both tissue (FFPE) and liquid biopsy samples with results delivered via AI-powered iCare platform.
- Clinical Research Services: Laboratory services for biopharma clinical trials including biomarker discovery, patient stratification, and companion diagnostic development using the OncoIncytes platform and 1080-gene NGS panel.
- Biopharma Partnerships: Collaborations with pharmaceutical companies for precision oncology solutions including trial support, biomarker validation, and data services for drug development programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise diagnostic testing services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
1Cell.Ai product offering
Product offeringCore offering
1Cell.Ai provides AI-driven single cell multi-omics precision oncology diagnostics through proprietary Cell Biopsy liquid biopsy technology that captures live circulating tumor cells (CTCs) and ctDNA from blood samples. The platform combines an AI-powered informatics suite (iCare/iCore) with a portfolio of NGS-based genomic profiling tests (OncoIndx, OncoRisk, OncoHRD, OncoMonitor, OncoTarget) for cancer detection, therapy selection, hereditary risk assessment, HRD testing, and longitudinal disease monitoring. Services are delivered through CLIA/CAP-certified laboratories in the US and NABL-accredited facilities in India, targeting clinicians, hospitals, biopharma companies, and researchers.
Product overview
1Cell.Ai offers a unified AI-powered single-cell multi-omics precision oncology platform. The portfolio is organized into two main offerings: (1) A global platform comprising OncoIncytes® (live CTC liquid biopsy), 1Cell SOLO® (automated single-cell isolation), and 1Cell iCore™ (AI informatics platform with iDiscover and iCare modules); and (2) An India-specific suite including OncoIndx® (comprehensive 1,000+ gene NGS profiling), OncoIndx® Prime+ (tissue-liquid-normal matched NGS), OncoRisk® (74-gene hereditary cancer panel), OncoHRD® (HRD testing for PARP inhibitor guidance), OncoMonitor® (longitudinal CTC/ctDNA monitoring), OncoTarget® (disease-specific targeted panels), OncoIndx® 360° Endometrium (WHO-aligned endometrial classification), and DrG and OSakhi (clinician and patient companion platforms). All products are supported by AI-powered interpretation through the iCare™ platform and are validated under CAP/CLIA/NABL/ISO quality systems.
Differentiator
Problem solved
Functional benefit
Products and services
- OncoIncytes® Proprietary next-generation liquid biopsy platform that captures and analyzes live circulating tumor cells (CTCs) in real time, combining CTC and ctDNA analysis to provide comprehensive molecular information for personalized therapeutic decisions in oncology.
- 1Cell SOLO®
Quantifiable outcome
- 4× earlier relapse detection through molecular-level signal vs. imaging
- +5 more outcomes
Companies that use 1Cell.Ai
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
1Cell.Ai technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability10 records
Feature6 records
1Cell.Ai partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- AccuGenomicscoreStrategic collaboration to integrate AccuGenomics' Accukit™ CRC/NSCLC Internal Standards with 1Cell.Ai's ultra-sensitive NGS-based OncoIndx panel for per-sample quality control and sensitivity verification. Partnership aims to process tens of thousands of patient samples annually across Asia with plans for US market expansion.
- Georgia Cancer Center / Dr. Ravindra KolhecoreCLIA-grade analytical validation study of OncoIncytes 1080-gene NGS panel at the Georgia Cancer Centre's GEM Lab, led by Dr. Ravindra Kolhe. Validation demonstrated high concordance with FDA-approved orthogonal NGS platforms across 15+ tumor types.
- BioSkryb GenomicscoreStrategic partnership to co-develop and commercialize next-generation single cell multi-omic solutions. Collaboration combines BioSkryb's single cell multi-omics technology with 1Cell.Ai's precision diagnostics platform for enhanced biomarker discovery and clinical applications.
- Academic and Research InstitutionsmajorCollaborative partnerships with leading academic institutions and research hospitals for multi-omic research, clinical validation studies, and biomarker discovery programs. Partner logos displayed on website indicating established relationships.
Scale indicators9 records
Recent moves7 records
Expansion highlights5 records
1Cell.Ai competitors and assessment
Company assessmentBroad incumbents
- Exact Sciences: Major diagnostics company with Cologuard plus the acquired Genomic Health/Thrive oncology assets (Oncotype DX). Broad incumbent offering oncology diagnostics and screening that competes for hospital and oncologist mindshare.
- Tempus: AI-powered precision medicine company offering multi-omic profiling, real-world evidence, and biopharma data services. Broad incumbent comparable to 1Cell.Ai's iCORE platform for biomarker-driven clinical trials and AI interpretation.
- Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx). Comparable as a broad oncology diagnostics incumbent with established payer coverage, biopharma CDx partnerships, and a multi-omic profiling offering that overlaps with 1Cell.Ai's OncoIndx panel.
- NeoGenomics: Specialized oncology laboratory services company with comprehensive genomic profiling, MRD, and pharma services. Broad incumbent with overlapping CGP, liquid biopsy, and biopharma clinical trial offerings.
Direct peers
- Personalis: Cancer genomics company with NeXT Personal MRD test and ImmunoID Next platform for tumor profiling. Direct peer in liquid biopsy MRD and immuno-oncology biomarker discovery, competing for biopharma partnership dollars.
- Guardant Health: Leading US liquid biopsy company with Guardant360 CDx and Reveal MRD products. Directly competes with 1Cell.Ai's OncoIncytes platform in oncology liquid biopsy and is the most relevant comparator given its commercial scale, Medicare coverage, and biopharma partnerships.
- Natera: Molecular diagnostics company with Signatera MRD test and oncology products. Direct peer in tumor-informed liquid biopsy and longitudinal monitoring — overlapping with 1Cell.Ai's OncoMonitor MRD and CTC/ctDNA strategy.
- Caris Life Sciences: Molecular profiling company offering tissue and liquid biopsy comprehensive genomic profiling plus AI-driven biomarker discovery (MI Profile, MI Cancer Seek). Direct competitor to 1Cell.Ai across the same oncology diagnostics and biopharma services segments.
Emerging players
- AccuGenomics: NGS quality control standards provider whose Accukit™ CRC/NSCLC Internal Standards integrate with 1Cell.Ai's OncoIndx panel per October 2025 partnership. Emerging peer/adjoiner enabling ultra-sensitive liquid biopsy QC.
- BioSkryb Genomics: Single-cell multi-omics company and 1Cell.Ai's strategic co-development partner (announced April 2025). Emerging peer with overlapping single-cell technology platform and joint go-to-market alignment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
1Cell.Ai social profiles
Digital presence1Cell.Ai compliance and trust
Trust signalCompliance5 records
1Cell.Ai financial estimates
Financial estimateRevenue estimate
Valuation estimate
1Cell.Ai leadership team
Management profileNumber of profiles
Profiles9 records
1Cell.Ai funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
1Cell.Ai M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 1Cell.Ai
What does 1Cell.Ai do?
1Cell.Ai provides AI-driven single cell multi-omics precision oncology diagnostics through proprietary Cell Biopsy liquid biopsy technology that captures live circulating tumor cells (CTCs) and ctDNA from blood samples. The platform combines an AI-powered informatics suite (iCare/iCore) with a portfolio of NGS-based genomic profiling tests (OncoIndx, OncoRisk, OncoHRD, OncoMonitor, OncoTarget) for cancer detection, therapy selection, hereditary risk assessment, HRD testing, and longitudinal disease monitoring. Services are delivered through CLIA/CAP-certified laboratories in the US and NABL-accredited facilities in India, targeting clinicians, hospitals, biopharma companies, and researchers.
Is 1Cell.Ai a public or private company?
1Cell.Ai is a private company. It is classified as unknown and is currently operating.
When was 1Cell.Ai founded?
1Cell.Ai was founded in 2019. It employs 101 to 250 people.
Where is 1Cell.Ai based?
1Cell.Ai is headquartered in Mumbai, India, in the Asia region.
How does 1Cell.Ai make money?
Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are clinical Research Services and biopharma Partnerships.
Who are 1Cell.Ai's main competitors?
Broad incumbents on record are Exact Sciences, Tempus, Foundation Medicine and NeoGenomics. Direct peers are Personalis, Guardant Health, Natera and Caris Life Sciences. Emerging players are AccuGenomics and BioSkryb Genomics.
Does 1Cell.Ai have an API?
No public API is recorded for 1Cell.Ai.
What industry is 1Cell.Ai in?
1Cell.Ai's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 6215 and its SIC code is 2835.